JP2022525223A5 - - Google Patents
Info
- Publication number
- JP2022525223A5 JP2022525223A5 JP2021555607A JP2021555607A JP2022525223A5 JP 2022525223 A5 JP2022525223 A5 JP 2022525223A5 JP 2021555607 A JP2021555607 A JP 2021555607A JP 2021555607 A JP2021555607 A JP 2021555607A JP 2022525223 A5 JP2022525223 A5 JP 2022525223A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- treatment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819642P | 2019-03-17 | 2019-03-17 | |
| US62/819,642 | 2019-03-17 | ||
| US201962819725P | 2019-03-18 | 2019-03-18 | |
| US62/819,725 | 2019-03-18 | ||
| PCT/US2020/023215 WO2020190977A1 (en) | 2019-03-17 | 2020-03-17 | Treatment of cancers using sephb4-hsa fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525223A JP2022525223A (ja) | 2022-05-11 |
| JP2022525223A5 true JP2022525223A5 (https=) | 2023-04-03 |
| JP7809324B2 JP7809324B2 (ja) | 2026-02-02 |
Family
ID=72520496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555607A Active JP7809324B2 (ja) | 2019-03-17 | 2020-03-17 | ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220249621A1 (https=) |
| EP (1) | EP3941512A4 (https=) |
| JP (1) | JP7809324B2 (https=) |
| KR (1) | KR20220015375A (https=) |
| CN (1) | CN113939309A (https=) |
| AU (1) | AU2020241963A1 (https=) |
| CA (1) | CA3133437A1 (https=) |
| WO (1) | WO2020190977A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
| US20230312732A1 (en) * | 2020-06-17 | 2023-10-05 | 4C Biomed Services Ltd. | Ephb2 antibody and use thereof in combination therapy |
| IL302006A (en) * | 2020-10-11 | 2023-06-01 | Agensys Inc | Methods for treating cancer with antibody-drug conjugates (ADC) that bind to proteins 191P4D12 |
| EP4308149A4 (en) * | 2021-03-18 | 2025-02-26 | Valery Krasnoperov | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
| KR20240053651A (ko) * | 2021-09-07 | 2024-04-24 | 바스진 테라퓨틱스, 인크. | 에프린b2 발현을 이용한 암의 진단 방법 |
| WO2023154948A1 (en) * | 2022-02-14 | 2023-08-17 | Vasgene Therapeutics Inc. | Ephrin type-b receptor 4 (ephb4) agents and production thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101932604A (zh) * | 2007-03-12 | 2010-12-29 | 瓦斯基因治疗公司 | EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途 |
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
-
2020
- 2020-03-17 AU AU2020241963A patent/AU2020241963A1/en active Pending
- 2020-03-17 JP JP2021555607A patent/JP7809324B2/ja active Active
- 2020-03-17 US US17/439,926 patent/US20220249621A1/en active Pending
- 2020-03-17 CA CA3133437A patent/CA3133437A1/en active Pending
- 2020-03-17 WO PCT/US2020/023215 patent/WO2020190977A1/en not_active Ceased
- 2020-03-17 CN CN202080036834.1A patent/CN113939309A/zh active Pending
- 2020-03-17 KR KR1020217033333A patent/KR20220015375A/ko active Pending
- 2020-03-17 EP EP20772615.9A patent/EP3941512A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525223A5 (https=) | ||
| Castelletti et al. | Anti-Mesothelin CAR T cell therapy for malignant mesothelioma | |
| Kong et al. | Immune checkpoint inhibitors: breakthroughs in cancer treatment | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| Xu et al. | The development of CAR design for tumor CAR-T cell therapy | |
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| WO2018187791A1 (en) | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods | |
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2020516681A5 (https=) | ||
| US20020155109A1 (en) | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 | |
| US20200405762A1 (en) | Cyclin a1 specific t cell receptors and uses thereof | |
| Bao et al. | Targeting epidermal growth factor receptor in non-small-cell-lung cancer: current state and future perspective | |
| Guo et al. | Empowering therapeutic antibodies with IFN-α for cancer immunotherapy | |
| JP2021502334A5 (https=) | ||
| CN113166778A (zh) | T细胞修饰 | |
| CN113717942A (zh) | 一种联合嵌合抗原受体和i型干扰素的免疫治疗方法及其应用 | |
| CN110194799B (zh) | 结合犬pd-1的抗犬pd-1抗体 | |
| CN113784986A (zh) | 间皮素特异性嵌合抗原受体及表达它的t细胞 | |
| JP2022520596A5 (https=) | ||
| JP2024542682A (ja) | 治療 | |
| Chen et al. | IL-21-and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma | |
| TW202328212A (zh) | Ｍａｇｅ—ａ４陽性癌症之治療 | |
| Rossari et al. | Treatment options for advanced hepatocellular carcinoma: the potential of biologics | |
| CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
| Gerber et al. | Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC |